Top Page
Everest Medicines Ltd.
(1952)
Everest Medicines Ltd. (1952) vs. iShares MSCI Hong Kong ETF (EWH)
Everest Medicines Ltd. Business Overview & Revenue Model
Everest Medicines Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 706.68M | 125.93M | 12.79M | 54.00K | 0.00 |
| Gross Profit | 528.89M | 91.52M | 8.15M | 31.00K | 0.00 |
| EBITDA | -670.04M | -744.63M | -198.91M | -972.78M | -683.03M |
| Net Income | -1.04B | -844.46M | -247.28M | -1.01B | -5.68B |
Balance Sheet | |||||
| Total Assets | 4.96B | 5.77B | 6.61B | 6.65B | 7.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.60B | 2.35B | 1.65B | 2.64B | 4.48B |
| Total Debt | 575.61M | 510.63M | 503.71M | 485.03M | 447.33M |
| Total Liabilities | 886.05M | 804.10M | 960.25M | 753.83M | 636.11M |
| Stockholders Equity | 4.07B | 4.97B | 5.65B | 5.89B | 6.84B |
Cash Flow | |||||
| Free Cash Flow | -744.92M | -1.04B | -1.59B | -1.71B | -991.83M |
| Operating Cash Flow | -679.51M | -769.19M | -1.16B | -729.94M | -471.90M |
| Investing Cash Flow | 974.40M | 752.50M | -1.03B | -975.82M | -519.93M |
| Financing Cash Flow | 37.80M | 10.10M | -25.31M | -76.51M | 5.64B |
Everest Medicines Ltd. Technical Analysis
Everest Medicines Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$11.75B | 12.85 | 7.25% | 4.43% | -1.81% | -3.79% | |
57 Neutral | HK$19.90B | ― | -6.35% | ― | 33.63% | 31.50% | |
54 Neutral | HK$12.99B | ― | -18.87% | ― | 16.35% | -49.63% | |
53 Neutral | HK$13.30B | ― | -55.68% | ― | ― | -4.33% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 16.99% | 1.69% | |
49 Neutral | HK$9.84B | ― | -51.40% | ― | 58.75% | -1310.16% | |
49 Neutral | HK$18.70B | ― | -23.03% | ― | 461.36% | -16.43% |
Everest Medicines Ltd. Corporate Events
Everest Medicines Ltd. successfully held its Annual General Meeting on June 27, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the re-election of executive directors, authorization for the board to fix directors’ remuneration, re-appointment of Ernst & Young as auditors, and granting of general mandates for share repurchase and issuance. The approval of performance target awards for key executives under the Pre-IPO ESOP was also confirmed, indicating strong shareholder support for the company’s strategic direction and leadership.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced that its controlling shareholder, CBC Group, plans to sell 25,000,000 shares, representing approximately 7.63% of the company’s issued share capital, to global long-only and healthcare specialist investors. This move aims to broaden the company’s shareholder base with high-quality investors to support its long-term growth. The company remains committed to its strategic focus areas, including increasing sales of its key products, advancing regulatory processes, and developing next-generation treatments, without any material changes to its business operations or financial position.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. has announced that its Annual General Meeting (AGM) will be held virtually on June 27, 2025. Key agenda items include the adoption of the company’s financial statements for 2024, re-election of executive directors, re-appointment of Ernst & Young as auditors, and granting of mandates to repurchase shares and issue additional shares. These resolutions aim to strengthen the company’s governance and operational flexibility, potentially enhancing its market position and shareholder value.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$48.32 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
Everest Medicines Ltd. announced that its drug NEFECON® has received full approval from China’s National Medical Products Administration for treating primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression. This approval marks NEFECON® as the first etiological treatment for IgAN to receive such approval in China, and it is already approved in the U.S. and Europe. The approval is based on successful results from the global Phase 3 NefIgArd clinical trial, which demonstrated significant benefits in kidney function and disease progression delay. NEFECON® is now commercially available in several regions, with further launches anticipated, potentially enhancing Everest Medicines’ market position and offering substantial benefits to IgAN patients.
Everest Medicines Limited, a company incorporated in the Cayman Islands, announced the removal of the ‘B’ marker from its stock short name. This change, effective from May 2, 2025, will see the company’s shares traded under the new stock short name ‘EVEREST MED’ in English and ‘雲頂新耀’ in Chinese, while retaining the stock code ‘1952’. This update reflects a strategic adjustment in the company’s market presence and may influence investor perception and trading activities.
Everest Medicines Limited announced that it has received approval from the Hong Kong Stock Exchange to dis-apply certain listing rules, resulting in the removal of the ‘B’ marker from its stock short name. This change reflects the company’s compliance with the market capitalization and revenue requirements, signifying its growth and stability in the biotechnology sector.
Everest Medicines Ltd. has announced a change in its company secretary, with Ms. Leah Liu resigning and Mr. King Hang Yeung being appointed as the new joint company secretary effective April 15, 2025. This change is part of the company’s ongoing efforts to strengthen its corporate governance. Additionally, the company has clarified an error in the calculation of restricted share units (RSUs) under its Pre-IPO Employee Stock Ownership Plan (ESOP), which impacts the reported outstanding and available shares as of June 30, 2024. These adjustments are crucial for maintaining transparency and accuracy in the company’s financial reporting, which is vital for stakeholders’ trust.
Everest Medicines Ltd. announced the grant of 4,451,533 options under its Post-IPO Share Option Scheme and 1,150,397 awards under its Pre-IPO ESOP, with some awards subject to shareholder approval. This move aims to attract, retain, and incentivize key personnel, enhancing operational efficiency and aligning with the company’s remuneration policy. The grants, especially to directors and senior managers, are seen as market competitive and consistent with the company’s strategic goals, potentially impacting its operational dynamics and stakeholder interests positively.